GEM 153

Drug Profile

GEM 153

Alternative Names: Gene Expression Modulator 153

Latest Information Update: 19 Feb 2004

Price : $50

At a glance

  • Originator Idera Pharmaceuticals
  • Class Antisense oligonucleotides; Antivirals
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 19 Feb 2004 Discontinued for Herpes simplex virus infections in USA (unspecified route)
  • 21 May 2001 Profile reviewed but no significant changes made
  • 19 Jan 1995 No-Development-Reported for Herpes simplex virus infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top